Unveiling the Molecular Features of SCLC With a Clinical RNA Expression Panel

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Translating gene expression profiles of small cell lung cancer (SCLC) into clinical applications is an underexplored area.
• Identifying reliable biomarkers is crucial for advancing SCLC diagnostics and therapeutics.

Purpose of the Study:

• To evaluate gene expression variations in SCLC to identify potential biomarkers.
• To assess the utility of RNA Salah Targeted Expression Panel (RNA STEP) for clinical-grade profiling of SCLC.

Main Methods:

• RNA expression profiling of 44 SCLC tumor samples using RNA STEP.
• RNA sequencing (RNA-Seq) and immunohistochemistry on independent SCLC cohorts.
• Correlation analysis of key genes (ASCL1, NEUROD1, POU2F3, YAP1) and their protein expression.
• Comparison of SCLC gene expression profiles with lung adenocarcinoma and squamous cell carcinoma.

Main Results:

• RNA STEP results showed high correlation with RNA-Seq and immunohistochemistry.
• ASCL1 was the dominant transcription regulator (74.2%), followed by NEUROD1 (20%) and POU2F3 (2.9%).
• SCLC samples exhibited heterogeneous gene expression between primary and metastatic sites and showed high expression of targetable genes (DLL3, EZH2, TERT, RET).
• SCLCs presented colder immune profiles compared to other lung cancers, with lower expression of HLA and immune checkpoint genes, except LAG3.

Conclusions:

• Clinical-grade SCLC RNA expression profiling is valuable for SCLC subtyping.
• This profiling aids in designing clinical trials and identifying patients for targeted therapies.